1. Home
  2. LPCN vs KTTA Comparison

LPCN vs KTTA Comparison

Compare LPCN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.36

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.48

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPCN
KTTA
Founded
1997
2020
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.1M
18.1M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
LPCN
KTTA
Price
$2.36
$0.48
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
64.8K
587.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
46.18
N/A
EPS
N/A
N/A
Revenue
$1,976,677.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$92.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$0.28
52 Week High
$12.37
$2.06

Technical Indicators

Market Signals
Indicator
LPCN
KTTA
Relative Strength Index (RSI) 44.16 34.28
Support Level $2.16 $0.48
Resistance Level $2.46 $0.86
Average True Range (ATR) 0.12 0.06
MACD -0.00 0.00
Stochastic Oscillator 6.25 25.69

Price Performance

Historical Comparison
LPCN
KTTA

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: